Imugene Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • IMU

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $0.02
  • (As of Friday Closing)

Imugene General Information

Description

Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

Contact Information

Website
www.imugene.com
Formerly Known As
Imugeneos Industries, Vostech
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4-6 Bligh Street, Level 12
  • Suite 12.01
  • Sydney, New South Wales 2000
  • Australia
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • 4-6 Bligh Street, Level 12
  • Suite 12.01
  • Sydney, New South Wales 2000
  • Australia

Imugene Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imugene Stock Performance

As of 13-Nov-2026, Imugene’s stock price is $0.02. Its current market cap is $13.6M with 554M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.02 - $0.27 $13.6M 554M 2.71M

Imugene Financials Summary

As of 30-Sep-2026, Imugene has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 18,920 26,579 49,954 190,884
EBITDA (68,251) (45,179) (98,582)
Net Income (71,358) (44,658) (98,091)
Total Assets 15,850 54,599 101,194
Total Debt 4,335 6,957 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Imugene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imugene‘s full profile, request access.

Request a free trial

Imugene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood
Drug Discovery
Sydney, Australia
5 As of 2008

Durham, NC
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Imugene Competitors (2)

One of Imugene’s 2 competitors is Argos Therapeutics, a Venture Capital-Backed company based in Durham, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Argos Therapeutics Venture Capital-Backed Durham, NC
Amphivena Therapeutics Venture Capital-Backed South San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

Imugene Patents

Imugene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12698512-B2 Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers Active 06-Nov-2023
US-20250146017-A1 Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers Active 06-Nov-2023
US-20260317787-A1 Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers Pending 06-Nov-2023
WO-2025101672-A1 Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers Inactive 06-Nov-2023
AU-2018904373-A0 Methods of treating proliferative disorders Inactive 16-Nov-2018
To view Imugene’s complete patent history, request access »

Imugene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imugene Investments & Acquisitions (5)

Imugene’s most recent deal was a Merger/Acquisition with Vaxinia for . The deal was made on 18-Nov-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vaxinia 18-Nov-2019 Merger/Acquisition Drug Discovery
City of Hope (CF33 oncolytic virus) 15-Jul-2019 Corporate Asset Purchase Buildings and Property
Baker Heart and Diabetes Institute (Immuno-Oncology Technology) 13-Dec-2016 Corporate Asset Purchase Buildings and Property
Biolife Science 23-Oct-2013 Merger/Acquisition Drug Discovery
Lingual Consegna 31-Jul-2012 Merger/Acquisition Drug Delivery
To view Imugene’s complete investments and acquisitions history, request access »

Imugene ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.43 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Imugene’s complete esg history, request access »

Imugene Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Imugene (Cell Therapy Manufacturing Facility in North Carolina) NC

Imugene FAQs

  • When was Imugene founded?

    Imugene was founded in 1986.

  • Where is Imugene headquartered?

    Imugene is headquartered in Sydney, Australia.

  • What is the size of Imugene?

    Imugene has 5 total employees.

  • What industry is Imugene in?

    Imugene’s primary industry is Drug Discovery.

  • Is Imugene a private or public company?

    Imugene is a Public company.

  • What is Imugene’s stock symbol?

    The ticker symbol for Imugene is IMU.

  • What is the current stock price of Imugene?

    As of 13-Nov-2026 the stock price of Imugene is $0.02.

  • What is the current market cap of Imugene?

    The current market capitalization of Imugene is $13.6M.

  • Who are Imugene’s competitors?

    Argos Therapeutics and Amphivena Therapeutics are competitors of Imugene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process